These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 25847373

  • 1. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
    Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK.
    Cancer; 2015 Jul 01; 121(13):2156-63. PubMed ID: 25847373
    [Abstract] [Full Text] [Related]

  • 2. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
    Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T, Radiation Therapy Oncology Group.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):168-73. PubMed ID: 15093913
    [Abstract] [Full Text] [Related]

  • 3. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA, Kollmeier MA, Abu-Rustum NR, Tew WP, Sonoda Y, Barakat RR, Alektiar KM.
    Gynecol Oncol; 2013 Sep 01; 130(3):436-40. PubMed ID: 23800696
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC study group.
    Lancet Oncol; 2018 Mar 01; 19(3):295-309. PubMed ID: 29449189
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC Study Group.
    Lancet Oncol; 2019 Sep 01; 20(9):1273-1285. PubMed ID: 31345626
    [Abstract] [Full Text] [Related]

  • 6. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.
    Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T.
    Gynecol Oncol; 2006 Oct 01; 103(1):155-9. PubMed ID: 16545437
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
    Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):110-6. PubMed ID: 17084542
    [Abstract] [Full Text] [Related]

  • 8. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL, PORTEC study group.
    Lancet Oncol; 2016 Aug 01; 17(8):1114-1126. PubMed ID: 27397040
    [Abstract] [Full Text] [Related]

  • 9. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD.
    J Clin Oncol; 2017 Jan 01; 35(1):56-62. PubMed ID: 28034064
    [Abstract] [Full Text] [Related]

  • 10. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM.
    Gynecol Oncol; 2013 Feb 01; 128(2):288-93. PubMed ID: 23159818
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
    Foad I, Sharawy I, Mostafa E, Margergis M, Hussein T.
    J Egypt Natl Canc Inst; 2007 Jun 01; 19(2):163-9. PubMed ID: 19034346
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Ito K, Tsutui T, Ogata T, Yoshioka Y, Ogawa K, Kimura T.
    Int J Gynecol Cancer; 2013 Sep 01; 23(7):1279-86. PubMed ID: 23835505
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial.
    Wang X, Shen Y, Zhao Y, Li Z, Gou H, Cao D, Yang Y, Qiu M, Li Q, Liu J, Yi C, Liao Z, Luo D, Xu F, Bi F.
    Eur J Surg Oncol; 2015 Aug 01; 41(8):1082-8. PubMed ID: 26033265
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ, Li HQ, Sheng XG, Du XL, Wang C, Lu CH, Pan CX.
    Int J Gynecol Cancer; 2015 Jul 01; 25(6):1058-65. PubMed ID: 25647254
    [Abstract] [Full Text] [Related]

  • 20. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
    Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W, Gaur R, Jhingran A.
    Int J Radiat Oncol Biol Phys; 2013 May 01; 86(1):83-90. PubMed ID: 23582248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.